OCA
PHAT icon

Octagon Capital Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Octagon Capital Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-455,000
Closed -$4.83M – 55
2024
Q1 		$4.83M Buy
455,000
+405,000
+810% +$3.44M 0.58% 38
2023
Q4 		$457K Buy
+50,000
New +$431K 0.07% 32

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Octagon Capital Advisors's PHAT Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2024, closing a stake of 455,000 shares — an estimated $4.83M sold.

Octagon Capital Advisors first reported a position in PHAT in Q4 2023 and held it in 2 quarters. The position peaked at $4.83M in Q1 2024. 114 funds tracked by Wall St. Rank hold PHAT as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Phathom Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 455,000 Phathom Pharmaceuticals shares in Q2 2024, an estimated $4.83M.
  • Octagon Capital Advisors first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Phathom Pharmaceuticals position peaked at $4.83M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.